Finding the Right Match: Who Should Opt for Anti–CTLA-4 and Programmed Cell Death Protein-1 Combination Therapy?
The emergence of immune checkpoint inhibitors (ICIs) has profoundly changed the landscape of cancer treatment. These agents have revolutionized the way we approach various malignancies, offering new hope to patients with previously limited therapeutic options. Currently, only anti–CTLA-4 antibodies have been approved for efficacy in combination with anti–programmed cell death protein-1 (anti–PD-1) (programmed death-ligand 1 [PD-L1]) antibodies in NSCLC. The available anti–CTLA-4 antibodies in NSCLC include nivolumab and tremelimumab, both of which were found to have considerable efficacy in enhancing antitumor immune responses.
